Determining the potency and molecular mechanism of action of insurmountable antagonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 710-723

  Kenakin, Terry ^a   Jenkinson, Stephen ^a   Watson, Christian ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; DARIFENACIN; FRI 73657; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RECEPTOR BLOCKING AGENT; SR 48 968; UNCLASSIFIED DRUG; VICRIVIROC;

ALLOSTERISM; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; CELL LINE, TUMOR; DRUG ANTAGONISM; DRUG DESIGN; HUMANS; KINETICS;

EID: 33751183557     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.107375     Document Type: Article

References (32)

1. Aiyar N, Baker E, Vickery-Clark L, Ohlstein EH, Gellai M, Fredrickson TA, Brooks DP, Weinstock J, Weidley EF, and Edwards RM (1995) Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist. Eur J Pharmacol 283:63-72.
2. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
3. Black JW, Jenkinson DH, and Kenakin TP (1980) Antagonists of an indirectly acting agonist: block by propranolol and sotalol of the action of tyramine on rat heart. Eur J Pharmacol 65:1-10.
4. Black JW and Leff P (1983) Operational models of pharmacological agonist. Proc R Soc Lond B Biol Sci 220:141-162.
5. Choppin A and Eglen RM (2001) Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol 132:835-842.
6. Christopoulos A (2000) Overview of receptor allosterism, in Current Protocols in Pharmacology (Enna SJ, Williams M, Ferkany JW, Porsolt RD, Kenakin TP, and Sullivan JP eds) Vol 1, pp 1.21.21-1.21.45, John Wiley and Sons, Inc., New York.
7. Christopolous A and Kenakin TP (2002) G-protein coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
8. Cook DA, Archibald L, and Kenakin TP (1980) Rate of formation and decay of aziridinium ion derived from various 2-haloalkylamines. Proc West Pharmacol Soc 23:365-368.
9. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
10. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740-754.
11. Feng Y, Broder CC, Kennedy PE, and Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (Wash DC) 272:872-877.
12. Gaddum JH (1937) The quantitative effects of antagonistic drugs. J Physiol (Lond) 89:7P-9P.
13. Gaddum JH (1957) Theories of drug antagonism. Pharmacol Rev 9:211-218.
14. Gaddum JH, Hameed KA, Hathway DE, and Stephens FF (1955) Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol 40:49-74.
15. Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58:1412-1423.
16. Jakubic J, Bacakova L, Lisa V, El-Fakahany EE, and Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179.
17. Kenakin TP (2004a) Allosteric modulators: the new generation of receptor antagonist. Mol Interv 4:222-229.
18. Kenakin TP (2004b) G-protein coupled receptors as allosteric machines. Receptors Channels 10:51-60.
19. Kenakin TP (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
20. Kerr KP, Thai B, and Coupar IM (2000) Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK2 receptors. Br J Pharmacol 131:1461-1467.
21. Lew MJ and Angus JA (1996) Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16:328-337.
22. Lew MJ, Ziogas J, and Christopoulos A (2000) Dynamic mechanisms of non-classical antagonism by competitive AT1 receptor antagonists. Trends Pharmacol Sci 21:376-381.
23. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Sbibayama S, Sagawa K, Fukushima D, Moravek J, et al. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78:8654-8662.
24. Meini S, Patacchini R, Lecci A, Quartara L, and Maggi CA (2000) Peptide and non-peptide bradykinin B2 receptor agonists and antagonists: a reappraisal of their pharmacology in guinea pig ileum. Eur J Pharmacol 409:185-194.
25. Moran JF, Triggle CR, and Triggle DJ (1969) The mechanism of action of 2-halogenoethylamines at the adrenergic α-receptor and a further investigation of the "spare receptor" hypothesis. J Pharm Pharmacol 21:38-47.
26. Nagasaw T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, and Kishimoto T (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (Lond) 382:635-638.
27. Paton WDM and Rang HP (1965) The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc R Soc Lond B Biol Sci 163:1-44.
28. Sachpatzidis A, Benton BK, Manfredis JP, Wang H, Hamilton A, Dohlman HG, and Lolis E (2003) Identification of allosteric peptide agonists of CXCR4. J Biol Chem 278:896-907.
29. 2 values and associated analysis. J Pharmacol Exp Ther 207:705-718.
30. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al. (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (Lond) 393:591-594.
31. Watson C, Jenkinson S, Kazmierski W, and Kenakin TP (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol 67:1268-1282.
32. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, and Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (Lond) 393:595-599.